Johnson & Johnson Announces First Commercial Installation of OTTAVA Surgical Robot

Commercial agreement marks the next milestone in bringing a new category of soft-tissue robotics to hospitals and patients across the United States

Installation at Memorial Hermann-Texas Medical Center builds on years of clinical collaboration, including recent clinical evaluation of the OTTAVA™ Robotic Surgical System in Roux-en-Y Gastric Bypass

OTTAVA™ received U.S. FDA Authorization in July for use in ten general surgery procedures within the upper abdomen

Johnson & Johnson has announced that Memorial Hermann-Texas Medical Center in Houston, Texas will be the first hospital to install the OTTAVA™ Robotic Surgical System, representing a major milestone in the commercial launch of the company’s next-generation soft-tissue robotic platform. Memorial Hermann will be the first hospital in the United States to utilize the system as part of Johnson & Johnson’s early access commercial program.

The installation follows U.S. Food and Drug Administration (FDA) De Novo authorization of the OTTAVA™ Robotic Surgical System in July 2026. The system became the world’s first FDA-authorized table-integrated soft-tissue robotic surgical system and is authorized for use in multiple procedures in general surgery, including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy, splenectomy, gastric sleeve, small bowel resection, appendectomy, lysis of adhesions, fundoplication and hiatal hernia repair.

“Today’s milestone is a significant step for Johnson & Johnson as we commercialize OTTAVA and continue building on our ambition to lead in surgical robotics,” said Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech, Johnson & Johnson. “As we bring OTTAVA to market, our focus goes beyond introducing a new technology. We will work alongside health systems and surgical teams, bringing the breadth of Johnson & Johnson to support expanding access to robotic surgery, improve workflow and procedural efficiencies, and address the evolving needs of care teams.”

OTTAVA was designed to address some of the most persistent challenges facing hospitals and surgical teams, including operating room space constraints, workflow complexity, growing demand for robotic-assisted surgery and increasing pressure on healthcare resources. By integrating four robotic arms into a standard-sized surgical table, OTTAVA is designed to help hospitals expand operating room capacity, streamline workflows and maintain procedural momentum. The system’s architecture includes software-controlled automation capabilities, next-generation instrumentation and compatibility with the Polyphonic™ Digital Ecosystem.

“We designed OTTAVA around the real-world challenges facing hospitals, surgeons and care teams, and collaboration has been fundamental to that process. Working with our first commercial customer is an important step toward realizing our vision of delivering a system designed for the surgeons who use it,” said Hani Abouhalka, Company Group Chair, Surgery, MedTech, Johnson & Johnson. “Our longstanding relationship with Memorial Hermann reflects the kind of partnership we believe is essential to advancing innovation: listening closely, learning from one another and working together to turn real-world insights into meaningful innovation. We look forward to supporting their use of OTTAVA and in the generation of clinical data and real-world evidence to further support the advancement of robotic surgery.”

Memorial Hermann-Texas Medical Center served as a clinical trial site to evaluate OTTAVA as part of the Investigational Device Exemption (IDE) program that supported regulatory authorization.

“I am passionate about bringing new technologies into surgery. I’ve had the opportunity to see this system evolve from early development through clinical trials and I believe it will make a meaningful difference for both surgeons and patients,” said Erik Wilson, M.D., Chief of minimally invasive and elective general surgery at UTHealth Houston, director of bariatric surgery at Memorial Hermann-Texas Medical Center, and lead investigator for FORTE clinical study. “This kind of collaboration is essential to advancing robotic surgery, and I’m looking forward to bringing this next chapter to Memorial Hermann.”

Johnson & Johnson will continue the commercial launch of OTTAVA with select customers in the U.S., focusing on early customer success while working in parallel to evaluate the platform in additional indications.

*Dr. Wilson is a paid consultant for Johnson & Johnson.

Source: Johnson & Johnson